DOI: 10.1177/17588359261458751 ISSN: 1758-8359

Atezolizumab and bevacizumab plus chemotherapy versus chemotherapy in non-small cell lung cancer after tyrosine kinase inhibitor failure

Moonki Hong, Junho Choi, Seoyoung Lee, Yun Beom Sang, Min Hee Hong, Ja Hyun Yeo, Joo-Hang Kim, Shinkyo Yoon, Chang Gon Kim, Hye Ryun Kim
Show PDF Cite

Background:

Determining an optimal treatment strategy after tyrosine kinase inhibitor (TKI) failure remains challenging in oncogene-driven non-small cell lung cancer (NSCLC).

Objectives:

We aimed to evaluate and compare the efficacy and safety of atezolizumab, bevacizumab, carboplatin, and paclitaxel (ABCP) versus pemetrexed plus carboplatin or cisplatin (PC) in patients with progressive NSCLC harboring EGFR , ALK , or ROS1 alterations after TKI failure.

Design:

Multicenter retrospective study.

Methods:

We analyzed 114 patients with NSCLC treated with either ABCP ( n  = 48) or PC ( n  = 66) post-TKI failure between November 2016 and July 2023. Treatment response, progression-free survival (PFS), overall survival (OS), and safety profiles were assessed.

Results:

Among 106 evaluable participants, the ABCP arm demonstrated a higher response rate (50.0%) than the PC arm (35.0%). During the median follow-up of 29.9 months, PFS was significantly prolonged in the ABCP arm compared with that in the PC arm (7.3 vs 3.0 months, respectively; hazard ratio (HR) 0.643; p  = 0.026), whereas OS showed no significant difference ( p  = 0.165). Subgroup analysis revealed notable improvements in PFS (7.2 vs 2.1 months, HR 0.235; p  < 0.001) and OS (11.0 vs 4.1 months, HR 0.418; p  = 0.001) in patients with three or more metastatic sites.

Conclusion:

ABCP significantly improved PFS compared with PC in patients with NSCLC that progressed despite prior TKI therapy. An OS benefit was observed in patients with three or more metastatic sites.

More from our Archive